Innovhem to present New data on single-cell quantification of HbF and HbS at the 2024 ASH Annual Meeting. One poster presentation to feature new data, highlighting the single-cell quantification of HbF and HbS on patients treated with hydroxyurea. Innovhem is a French...
Innovhem’s patents protect our BIOMARKERS : An important news ! SINGLE CELL QUANTIFICATION OF FETAL HEMOGLOBIN patent has been issued in France, Nigeria and in the US. And our 2 patents cover INTRAVASCULAR HEMOLYSIS ASSAY in Europe and in the US. Stay tuned for...
HEMOPROVE is an Open-label One Stage Phase II study sponsored by AP-HP. The investigator hypothesis is that the treatment by Voxelotor (GBT440) will improve intra vascular hemolysis and will increase the total mass of hemoglobin with beneficial effects on organ...
Innovhem is proud to be part of the first promotion of the french accelerator for digital health prevention ! BPI France and PariSanté Campus have set up a high-level program to support 20 French companies and strengthen their strategy to accelerate the market launch...
